Max Healthcare Institute is preparing to report its Q1 FY27 results, a pivotal quarter where the company aims to demonstrate the full impact of recent capacity expansions and regulatory tailwinds. Investors will be focused on the margin-accretive potential of newly commissioned brownfield towers and the realization of the full run-rate benefit from the CGHS super-specialty rate revision.
| Results date | August 13, 2026 |
|---|---|
| Quarter | Q1 FY27 |
| Previous quarter revenue | Rs. 2,541 Cr |
| Previous quarter PAT | Rs. 387 Cr |
| Previous quarter EBITDA margin | 26.8% |
| Net debt (latest quarter) | Rs. 1,908 Cr |
| Market cap | Rs. 1,01,122.76 Cr |
| CMP | Rs. 1,040.0 |
The company will hold a board meeting on August 13, 2026, to consider the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.
An earnings call is scheduled for August 14, 2026, at 11:00 am IST to discuss the Q1 FY27 results.
Max Healthcare enters Q1 FY27 with a strong seasonal tailwind as early vector-borne disease trends in Delhi and Karnataka signal an active pre-monsoon hospitalisation environment. The quarter is expected to reflect the full materialisation of the CGHS super-specialty rate revision, with management previously guiding for a net sustained annual margin impact of Rs. 140 Cr. Operational leverage is anticipated to improve as newly commissioned capacities at Max Smart Saket, Mohali, and Nanavati Max transition from initial ramp-up phases toward higher EBITDA margins. The company's focus remains on integrating the recently acquired Kalinga Hospital while navigating the elevated doctor compensation costs associated with its aggressive 20-25% capacity expansion plan. The upcoming call will likely address the trajectory of oncology OBD volumes following the discontinuation of certain high-value drugs and the impact of new IRDAI cashless-settlement mandates on operational efficiency.
Performance vs Guidance Tracking: Tracking the realization of key financial and operational targets set by management.
Capacity Ramp-up Status: Monitoring the operational progress of recent brownfield and M&A additions.
Risks and headwinds to monitor: Key operational and regulatory challenges impacting the current quarter.
As of the Q4 FY26 earnings call, the company had realized Rs. 100-110 Cr of the projected Rs. 200 Cr gross top-line benefit. Management expected the remaining Rs. 30-40 Cr to flow through starting in Q1 FY27.
As of March 31, 2026, the company reported a net debt of Rs. 1,908 Cr. This maintains a net debt-to-EBITDA ratio of below 1.0x.
Management has stated that brownfield capacity should immediately operate at higher EBITDA margins compared to the existing network. This is expected to support overall margin expansion as these new towers fill up.